Abstract
AMP-activated protein kinase (AMPK) is an enzyme that works as a fuel gauge, being activated in situations of high-energy phosphate depletion. Upon activation, AMPK functions to restore cellular ATP by modifying diverse metabolic pathways. AMPK is activated robustly by skeletal muscle contraction and myocardial ischemia, and may be involved in the stimulation of glucose transport and fatty acid oxidation produced by these stimuli. In liver, activation of AMPK results in enhanced fatty acid oxidation and in decreased production of glucose, cholesterol, and triglycerides. Recent studies have shown that AMPK is the cellular mediator for many of the metabolic effects of drugs such as metformin and thiazolidinediones, as well as the insulin sensitizing adipocytokines leptin and adiponectin. These data, along with evidence from studies showing that chemical activation of AMPK in vivo with 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) improves blood glucose concentrations and lipid profiles, make this enzyme an attractive pharmacological target for the treatment of type 2 diabetes and other metabolic disorders.
Keywords: AMPK, ACC, exercise, glucose transport, type 2 diabetes mellitus
Current Medicinal Chemistry
Title: AMP-Activated Protein Kinase and Type 2 Diabetes
Volume: 13 Issue: 5
Author(s): Nicolas Musi
Affiliation:
Keywords: AMPK, ACC, exercise, glucose transport, type 2 diabetes mellitus
Abstract: AMP-activated protein kinase (AMPK) is an enzyme that works as a fuel gauge, being activated in situations of high-energy phosphate depletion. Upon activation, AMPK functions to restore cellular ATP by modifying diverse metabolic pathways. AMPK is activated robustly by skeletal muscle contraction and myocardial ischemia, and may be involved in the stimulation of glucose transport and fatty acid oxidation produced by these stimuli. In liver, activation of AMPK results in enhanced fatty acid oxidation and in decreased production of glucose, cholesterol, and triglycerides. Recent studies have shown that AMPK is the cellular mediator for many of the metabolic effects of drugs such as metformin and thiazolidinediones, as well as the insulin sensitizing adipocytokines leptin and adiponectin. These data, along with evidence from studies showing that chemical activation of AMPK in vivo with 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) improves blood glucose concentrations and lipid profiles, make this enzyme an attractive pharmacological target for the treatment of type 2 diabetes and other metabolic disorders.
Export Options
About this article
Cite this article as:
Musi Nicolas, AMP-Activated Protein Kinase and Type 2 Diabetes, Current Medicinal Chemistry 2006; 13 (5) . https://dx.doi.org/10.2174/092986706776055724
DOI https://dx.doi.org/10.2174/092986706776055724 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry Cardiac Stem Cell-Based Myocardial Regeneration: Towards a Translational Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry Hydrogen Sulfide Prevents Hyperoxia-induced Lung Injury by Downregulating Reactive Oxygen Species Formation and Angiopoietin-2 Release
Current Pharmaceutical Design Hypertension and Ischemic Heart Disease in Women
Current Pharmaceutical Design Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Editorial [Hot Topic:Modifying Cardiovascular Risk Factors: Newer Insights and Preventive Measures (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents
Current Pharmaceutical Design Atrial Fibrillation Following Cardiac Surgery: Established and Emerging Strategies of Prevention
Recent Patents on Cardiovascular Drug Discovery Preconditioning of the Myocardium by Volatile Anesthetics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Churg-Strauss Syndrome Presenting as Acute Necrotizing Eosinophilic Myocarditis: Concise Review of the Literature
Current Hypertension Reviews The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Screening, Evaluation, and Early Management of Acute Aortic Dissection in the ED
Current Cardiology Reviews Coronary Risk Assessment and Management Options in Chronic Kidney Disease Patients Prior to Kidney Transplantation
Current Cardiology Reviews Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals
Current Pharmaceutical Design Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design MicroRNA-16-5p Aggravates Myocardial Infarction Injury by Targeting the Expression of Insulin Receptor Substrates 1 and Mediating Myocardial Apoptosis and Angiogenesis
Current Neurovascular Research Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy